Navigating an Increasingly Complex Treatment Paradigm in the Management of Advanced Renal Cell Carcinoma (RCC): A Close Look at New and Emerging Combinations

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2021 Fall Managed Care Forum.
If you participated in the live session, you are not eligible for continuing
education credits from this archive.

This activity is valid from January 1, 2022, to March 1, 2023.
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Eisai and Merck Sharp & Dohme Corp.

Description:
Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. In 2021, it is estimated that there will be approximately 76,080 new cases of kidney cancer, and about 13,780 people will die from the disease. Approximately 16% of patients with RCC will have metastases at diagnosis, and as many as 40% will demonstrate metastasis after primary surgical treatment for localized RCC. With a 5-year survival rate ranging from 5% to 12%, the prognosis for these patients is poor. Fortunately for patients with advanced RCC, several new treatments have recently become available or are undergoing clinical trials giving clinicians new options to improve patient outcomes and quality of life, especially in first-line settings and combination regimens. This activity will
focus on these evolving options, how to integrate them into the treatment paradigm, and how to apply evidence-based data to select appropriate treatment regimens and manage toxicities.

Upon completion of this activity, participants will be able to:

  • Evaluate the clinical and economic burden of advanced renal cell carcinoma (RCC) in terms of relative survival, mortality, drug utilization, adverse event management, and hospitalizations

  • Analyze recent efficacy and safety data on new treatment approaches, including targeted TKIs, immune-oncology (IO) agents, and novel combination approaches, for advanced renal cell carcinoma (RCC)

  • Assess the evolving role of TKI and immunotherapy combinations in the first-line management of advanced RCC

  • Integrate recent clinical research findings on validated TKI and IO-based options into the development of individualized treatment plans for patients with newly diagnosed and previously treated advanced RCC

  • Discuss strategies to monitor and manage adverse events associated with TKI and immunotherapy combinations in advanced RCC in order to improve patient adherence and quality of life

  • Examine the managed care considerations of current and emerging TKI and immunotherapy combinations by exploring where these agents fit into the current advanced RCC management paradigm

     

Faculty: Neeraj Agarwal, MD
Professor of Medicine
Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)

Disclosure:

Dr. Agarwal has served as a consultant for Astellas, Astra Zeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. He has received grant/research support from Astra Zeneca, Bavarian Nordic , Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. His presentation has been peer reviewed for any bias.
Planning Committee: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Eisai and Merck Sharp & Dohme Corp.


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue